Search clinical trials for: Veliparib

Total 109 results

AbbVie

Completed

To Determine the Food Effect and Bioavailability of Three Formulations of Veliparib in Subjects With Solid Tumors

Solid Tumors
AbbVie

Completed

A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors

Advanced Solid Tumors

Japan
University of Alabama at Birmingham
GlaxoSmithKline; AbbVie; Breast Cancer Research Foundation of Alabama

Active, not recruiting

Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer

Metastatic Triple Negative Breast Cancer

United States
AbbVie (prior sponsor, Abbott)

Completed

A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases

Brain Diseases | Central Nervous System Diseases | Neoplasm Metastasis | Brain Neoplasms | Nervous System Neoplasms

United States, Canada, Puerto Rico
AbbVie

Completed

A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors

Breast Cancer | Gastric Cancer | Ovarian Cancer | Lung Cancer | Colon Cancer | Solid Tumors

United States, Netherlands, Spain
National Cancer Institute (NCI)

Completed

Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors

Neoplasms

United States
Abbott

Completed

To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors

Solid Tumor Cancers

United States
AbbVie (prior sponsor, Abbott)

Completed

Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor

Gastric Cancer

United States, Korea, Republic of
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer

Lymphoma | Leukemia | Unspecified Adult Solid Tumor, Protocol Specific

United States
AbbVie

Withdrawn

A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer

Cancer - Ovarian
AbbVie (prior sponsor, Abbott)

Completed

A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma

Melanoma | Skin Cancer | Metastatic Melanoma
AbbVie

Terminated

A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer Stage III

United States
AbbVie

Completed

Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer

Ovarian Cancer

Japan
AbbVie (prior sponsor, Abbott)

Completed

A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer

United States, Australia
Central European Society for Anticancer Drug Research

Unknown

Study in Patients With SCLC of Veliparib in Combination With Topotecan

Small Cell Lung Cancer SCLC

Germany
Steven J Isakoff, MD, PhD
Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Abbott

Active, not recruiting

ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer

Breast Cancer | Metastatic Breast Cancer | BRCA1 Gene Mutation | brca2 Gene Mutation

United States
AbbVie (prior sponsor, Abbott)
Prostate Cancer Clinical Trials Consortium

Completed

A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer

Prostate Cancer
University Hospital, Caen

Completed

Pancytopenia Related to PARP Inhibitors (PancytoRIB)

Cancer

France
AbbVie (prior sponsor, Abbott)

Completed

A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors

Advanced Solid Tumors
Vejle Hospital
Abbott

Completed

Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation (Veli-BRCA)

Recurrent, Epithelial Ovarian Cancer

Denmark
University Hospital, Caen

Completed

Arterial Hypertension Related to PARP Inhibitors (ArteRIB)

Cancer

France
National Cancer Institute (NCI)

Completed

ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors

Recurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Childhood Atypical Teratoid/Rhabdoid Tumor | Childhood Choroid Plexus Tumor | Childhood Craniopharyngioma | Childhood Ependymoblastoma | Childhood Grade I Meningioma | Childhood Grade II Meningioma | Childhood Grade III Meningioma | Childhood High-grade Cerebellar Astrocytoma and other conditions

United States
AbbVie

Completed

A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

Metastatic Breast Cancer

United States, Argentina, Australia, Austria, Belarus, Belgium, Canada, Chile, Colombia, Czechia, Denmark, Estonia, Finland, France, Germany, Hungary, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Mexico, Netherlands, Norway, Po... and more
AbbVie

Completed

A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors

Oncology | High Grade Serous Ovarian Cancer | BRCA Mutated | BRCA Mutated Breast Cancer
AbbVie

Completed

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

Squamous Non-Small Cell Lung Cancer

United States, Australia, Austria, Belarus, Brazil, Canada, Croatia, Czechia, Denmark, Egypt, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Latvia, Lithuania, Mexico, Netherlands, New Zealand, Norway, Poland, P... and more
AbbVie (prior sponsor, Abbott)

Completed

A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid Tumors

Solid Tumors

Japan
AbbVie
Gynecologic Oncology Group;Australia New Zealand Gynaecological Oncology...

Terminated

Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (VELIA)

Ovarian Cancer | Ovarian Neoplasm

United States, Australia, Brazil, Denmark, Israel, Japan, Korea, Republic of, New Zealand, Poland, Spain, United Kingdom
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Brain and Central Nervous System Tumors

United States
Richard Zellars

Suspended

Pre-Operative Radiation and Veliparib for Breast Cancer

Breast Cancer

United States
University Medical Center Groningen
AbbVie; Dutch Cancer Society

Withdrawn

Response to PARP Inhibitor Predicted by the RAD51 Assay (REPAIR)

Cancer
National Cancer Institute (NCI)

Terminated

Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Regional Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage... and other conditions

United States
AbbVie (prior sponsor, Abbott)

Completed

A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer

Ovarian Cancer

United States, Australia, Canada, Hungary, Israel, New Zealand, Poland, United Kingdom
University of Washington
National Cancer Institute (NCI)

Completed

Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast Cancer | Hereditary Breast/Ovarian Cancer - BRCA1 | Hereditary Breast/Ovarian Cancer...

United States
AbbVie

No longer available

Expanded Access to Veliparib

High Grade Serous Ovarian Cancer | Solid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically Sound | Triple Negative Breast Cancer (TNBC) | Patients Requiring Veliparib Suspension Formulation
National Cancer Institute (NCI)

Terminated

Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific | Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IV Breast Cancer | Stage IV Ovarian Epithelial Cancer | Stage IV Ovarian Germ Cell Tumor | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB... and other conditions

United States
University of Michigan Rogel Cancer Center

Completed

Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer

Breast Cancer

United States
The University of Texas Health Science Center at...

Withdrawn

Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients

Ovarian Cancer | Breast Cancer Stage IV | BRCA1 Mutation | BRCA2 Mutation
AbbVie

Completed

Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Breast Carcinoma | Ovarian Carcinoma | Pancreatic Carcinoma | Prostate Carcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative... and other conditions

United States
AbbVie (prior sponsor, Abbott)

Completed

Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung Cancer

Brain Metastases From Non-small Cell Lung Cancer
Vejle Hospital
Abbott

Completed

Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status

Ovarian Cancer

Denmark
Novo Nordisk A/S

Terminated

Comparison of Insulin Detemir and NPH Insulin Given Once Daily in Ageing Subjects With Type 2 Diabetes (3L)

Diabetes Mellitus, Type 2 | Diabetes

United Kingdom, France
Georgetown University
Abbott

Terminated

ABT-888 and Temozolomide for Liver Cancer

Hepatocellular Carcinoma

United States
National Cancer Institute (NCI)

Completed

A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors

Astrocytoma | Ependymoma | Medulloblastoma | Pontine Glioma | PNET

United States
Georgetown University
Abbott

Completed

A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer

Colorectal Cancer

United States
AbbVie

Completed

Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer

Small Cell Lung Cancer

United States, Australia, Belgium, Canada, Czechia, France, Hungary, Korea, Republic of, Netherlands, Romania, Russian Federation, Spain
AbbVie

Completed

A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients

Breast Cancer | Hepatocellular Carcinoma | Ovarian Cancer | Fallopian Tube Cancer | Metastatic Melanoma | Primary Peritoneal Cancer | Non-hematologic Malignancies
AHS Cancer Control Alberta
Abbott; Tom Baker Cancer Centre

Completed

Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma

Multiple Myeloma

Canada
National Cancer Institute (NCI)

Completed

Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas

Solid Tumors | Lymphomas

United States
National Cancer Institute (NCI)

Withdrawn

ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems

Neoplasms

United States

Search clinical trials for: Veliparib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations